Short Interest in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Increases By 201.6%

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totalling 37,100 shares, a growth of 201.6% from the March 31st total of 12,300 shares. Based on an average daily volume of 39,300 shares, the short-interest ratio is presently 0.9 days.

ProShares Ultra Nasdaq Biotechnology Trading Up 1.8 %

NASDAQ:BIB traded up $0.86 during mid-day trading on Friday, hitting $49.80. 7,393 shares of the company’s stock were exchanged, compared to its average volume of 38,478. ProShares Ultra Nasdaq Biotechnology has a one year low of $40.10 and a one year high of $62.45. The business has a fifty day moving average price of $55.69 and a 200 day moving average price of $52.59.

ProShares Ultra Nasdaq Biotechnology Announces Dividend

The firm also recently disclosed a dividend, which was paid on Wednesday, March 27th. Investors of record on Thursday, March 21st were paid a dividend of $0.0403 per share. The ex-dividend date of this dividend was Wednesday, March 20th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of BIB. IMC Chicago LLC purchased a new position in ProShares Ultra Nasdaq Biotechnology in the fourth quarter worth about $2,435,000. Toth Financial Advisory Corp raised its holdings in shares of ProShares Ultra Nasdaq Biotechnology by 132.3% during the first quarter. Toth Financial Advisory Corp now owns 26,111 shares of the exchange traded fund’s stock valued at $1,502,000 after purchasing an additional 14,870 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of ProShares Ultra Nasdaq Biotechnology by 523.9% during the third quarter. Tower Research Capital LLC TRC now owns 6,457 shares of the exchange traded fund’s stock valued at $310,000 after purchasing an additional 5,422 shares during the last quarter. Palumbo Wealth Management LLC purchased a new position in shares of ProShares Ultra Nasdaq Biotechnology during the fourth quarter valued at approximately $228,000. Finally, Clarity Capital Partners LLC purchased a new position in shares of ProShares Ultra Nasdaq Biotechnology during the fourth quarter valued at approximately $201,000.

About ProShares Ultra Nasdaq Biotechnology

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.